Na Vang, DO
Family Medicine · Pearland, TXNPI 1518399344
Payments from drug & device makers
Across 145 payments — averaging $17.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$537
- Amgen$318
- Novo Nordisk$268
- Boehringer Ingelheim$192
- Sumitomo Pharma America, Inc.$144
- Lilly USA, LLC$141
- plus $930 from 19 others
What the payments were for
- Food & beverage$2,522100%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 33 | $537 |
| Amgen | 20 | $318 |
| Novo Nordisk | 16 | $268 |
| Boehringer Ingelheim | 10 | $192 |
| Sumitomo Pharma America, Inc. | 8 | $144 |
| Lilly USA, LLC | 8 | $141 |
| Sanofi-aventis U.S. LLC | 7 | $130 |
| Novartis | 6 | $87 |
| GSK | 5 | $85 |
| Dexcom, Inc. | 1 | $71 |
| Merck | 4 | $66 |
| Exact Sciences | 4 | $65 |
| Medtronic | 1 | $62 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $54 |
| Pfizer | 3 | $49 |
| AbbVie | 3 | $46 |
| Shire North American Group Inc | 2 | $37 |
| Astellas Pharma US Inc | 2 | $35 |
| Mylan Specialty L.p. | 1 | $29 |
| Regeneron Healthcare Solutions, Inc. | 2 | $29 |
| Aimmune Therapeutics, Inc. | 1 | $23 |
| Johnson & Johnson | 1 | $18 |
| Genentech USA, Inc. | 1 | $17 |
| IBSA Pharma Inc. | 1 | $14 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
How this compares
$2,528 in reported general payments places this provider in the 75th percentile of 8,760 family medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Levocetirizine Dihydrochloride | 68 | $470 |
| Fluticasone Propionate | 95 | $411 |
| Triamcinolone Acetonide | 39 | $343 |
| Diclofenac Sodium | 19 | $334 |
| Mometasone Furoate | 11 | $269 |
| Betamethasone Dipropionate | 16 | $241 |
| Memantine Hcl | 21 | $230 |
| Losartan Potassium | 53 | $189 |
| Atorvastatin Calcium | 62 | $185 |
| Gabapentin | 26 | $171 |
| Azelastine Hcl | 15 | $155 |
| Famotidine | 27 | $114 |
| LoperamideLoperamide Hcl | 19 | $102 |
| Ammonium Lactate | 11 | $94 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 17 | $87 |
Paid to pharmacies, not to this prescriber.
Other family medicine in Pearland
- Douglas DenhamSan Antonio$68.5M
- Vicki MillerPasadena$58.3M
- Hareshkumar BogharaDesoto$30.3M
- Earl MartinTomball$30.1M
- Lisa HollowayHouston$30.1M
- William SegerFort Worth$27.5M
- Veronica FragosoHouston$24.5M
- Joel SolisMcAllen$21.1M
- George AtieeSan Antonio$19.9M
- Bonnie ColvilleHouston$19.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.